Vaccines
28 February 2021
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan25 February 2021
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ — a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate25 February 2021
AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-1925 February 2021
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants25 February 2021
Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study24 February 2021
U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)24 February 2021
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan23 February 2021
INOVIO announces first subject dosed in Phase 1B clinical trial for its DNA vaccine against Lassa fever, INO-4500, in West Africa22 February 2021
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate22 February 2021
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico22 February 2021
Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer20 February 2021
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA20 February 2021
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine19 February 2021
Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women18 February 2021
Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine17 February 2021
Altimmune Announces FDA Clearance of AdCOVID™ IND Application16 February 2021
AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization12 February 2021
CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV10 February 2021
AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity8 February 2021
Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine8 February 2021
COVAXX’s COVID-19 Vaccine, UB-612, Induced Neutralizing Antibodies in 100% of Participants During Phase 1 Clinical Trial6 February 2021
Science Advances: Elicio Therapeutics’ SARS-CoV-2 Vaccine Demonstrates T Cell Responses >25 Fold Higher Than Benchmark Vaccines6 February 2021
Sinovac Announces Phase III Results of Its COVID-19 VaccineNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports